Alzheon

Framingham, MA · Founded 2013 · Privately Held (backing)

Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders. Alzheon is based in Framingham, MA and was founded in 2013. Its last reported valuation was $550 million in Apr 2022. It has raised $212 million across 9 recorded rounds; the latest was a $126 million later-stage round in Feb 2024.

Last reported valuation
$550.0M
Oct 2026
Priced at
—
Total raised
$212.2M
Last round
Later Stage VC
Feb 2024

Who backs Alzheon?

8 investors
InvestorType
Ally Bridge GroupGrowth equity
HCL CapitalFamily office
Alerce Investment Management—
Aptorum Group—
Ron Sachs—
Scott Cohen—
The National Institute on Aging (NIA)—
Thornapple River Capital—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Alzheon investors

8 investors are on record for Alzheon, including Ally Bridge Group, HCL Capital, Alerce Investment Management and Aptorum Group. The later-stage round in Feb 2024 drew 76 investors.

Free account
More of Alzheon with a free account
  • ·Watch Alzheon: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 8 firms already write checks for companies like Alzheon. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View